IL137510A0 - Compositions comprising viruses and methods for concentrating virus preparations - Google Patents

Compositions comprising viruses and methods for concentrating virus preparations

Info

Publication number
IL137510A0
IL137510A0 IL13751099A IL13751099A IL137510A0 IL 137510 A0 IL137510 A0 IL 137510A0 IL 13751099 A IL13751099 A IL 13751099A IL 13751099 A IL13751099 A IL 13751099A IL 137510 A0 IL137510 A0 IL 137510A0
Authority
IL
Israel
Prior art keywords
viruses
compositions
methods
virus preparations
concentrating virus
Prior art date
Application number
IL13751099A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL137510A0 publication Critical patent/IL137510A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13751099A 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations IL137510A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (1)

Publication Number Publication Date
IL137510A0 true IL137510A0 (en) 2001-07-24

Family

ID=26698472

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13751099A IL137510A0 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations
IL137510A IL137510A (en) 1998-02-17 2000-07-25 Vaccines for maintaining the stability of adenoviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137510A IL137510A (en) 1998-02-17 2000-07-25 Vaccines for maintaining the stability of adenoviruses

Country Status (25)

Country Link
EP (4) EP1526174B1 (es)
JP (3) JP4358434B2 (es)
KR (5) KR101018992B1 (es)
CN (2) CN101164623B (es)
AR (3) AR020054A1 (es)
AT (3) ATE478945T1 (es)
AU (1) AU757976B2 (es)
BR (1) BR9908015A (es)
CA (2) CA2320419C (es)
CO (1) CO4820440A1 (es)
DE (3) DE69936948T2 (es)
DK (1) DK1054955T3 (es)
ES (2) ES2272053T3 (es)
HK (3) HK1073481A1 (es)
HU (1) HU226015B1 (es)
ID (1) ID28298A (es)
IL (2) IL137510A0 (es)
MY (1) MY141641A (es)
NO (1) NO20004104L (es)
PE (1) PE20000265A1 (es)
PL (1) PL197747B1 (es)
PT (1) PT1054955E (es)
SK (1) SK11842000A3 (es)
TW (1) TWI232107B (es)
WO (1) WO1999041416A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
ES2323991T3 (es) * 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A8 (en) * 2000-12-12 2008-01-17 Japan Tobacco Inc Pharmaceutical composition containing an active with a hemolytic action and a surfactant
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
RU2004125283A (ru) * 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) Стабилизированные композиции аденовируса
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
EP1815029A4 (en) 2004-11-03 2009-06-10 Introgen Therapeutics Inc NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
ATE516343T1 (de) 2004-12-13 2011-07-15 Canji Inc Zellinien zur produktion von replikationsdefektem adenovirus
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
US20070249043A1 (en) 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors
CN101426905B (zh) * 2006-04-20 2013-03-27 惠氏公司 从细胞培养物分离纯化的水泡性口炎病毒的纯化方法
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
CN102459611B (zh) 2009-05-02 2016-11-09 建新公司 神经退行性疾病的基因治疗
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
JP6034798B2 (ja) * 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
BR112014023196B1 (pt) 2012-03-22 2021-09-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
US10280195B2 (en) * 2014-05-28 2019-05-07 Agency For Science, Technology And Research Virus reduction method
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
MA43763B1 (fr) 2016-04-05 2021-03-31 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
CN114173827A (zh) * 2019-06-28 2022-03-11 武田药品工业株式会社 腺相关病毒纯化方法
US11498944B2 (en) 2020-01-31 2022-11-15 Janssen Pharmaceuticals, Inc. Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
KR20230147156A (ko) 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (es) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
EP1526173B1 (en) 2012-11-21
EP1526174A3 (en) 2005-08-31
DK1054955T3 (da) 2007-01-15
JP4358434B2 (ja) 2009-11-04
SK11842000A3 (sk) 2001-05-10
KR100991683B1 (ko) 2010-11-04
EP1526174A2 (en) 2005-04-27
TWI232107B (en) 2005-05-11
WO1999041416A2 (en) 1999-08-19
EP1526173A2 (en) 2005-04-27
BR9908015A (pt) 2001-04-24
AR063315A2 (es) 2009-01-21
CN1297478A (zh) 2001-05-30
AR063314A2 (es) 2009-01-21
DE69933433D1 (de) 2006-11-16
HK1097413A1 (en) 2007-06-22
ATE341614T1 (de) 2006-10-15
DE69933433T2 (de) 2007-08-23
PL197747B1 (pl) 2008-04-30
KR100862169B1 (ko) 2008-10-09
CA2320419A1 (en) 1999-08-19
EP1741777B1 (en) 2010-08-25
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
HUP0100670A2 (hu) 2001-06-28
KR20090127947A (ko) 2009-12-14
EP1526174B1 (en) 2007-08-22
HU226015B1 (en) 2008-02-28
CA2320419C (en) 2011-02-08
NO20004104L (no) 2000-10-17
AU2653899A (en) 1999-08-30
KR20080065615A (ko) 2008-07-14
PL342847A1 (en) 2001-07-16
DE69936948D1 (de) 2007-10-04
CA2723040A1 (en) 1999-08-19
CN101164623A (zh) 2008-04-23
CN100374551C (zh) 2008-03-12
HK1073481A1 (en) 2005-10-07
MY141641A (en) 2010-05-31
KR20010072547A (ko) 2001-07-31
WO1999041416A3 (en) 1999-11-18
CO4820440A1 (es) 1999-07-28
PT1054955E (pt) 2007-01-31
NO20004104D0 (no) 2000-08-16
IL137510A (en) 2012-10-31
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
PE20000265A1 (es) 2000-04-25
KR100918187B1 (ko) 2009-09-22
ATE371020T1 (de) 2007-09-15
KR20080065614A (ko) 2008-07-14
CN101164623B (zh) 2012-11-14
ES2290613T3 (es) 2008-02-16
JP2010213727A (ja) 2010-09-30
DE69942708D1 (de) 2010-10-07
EP1526173A3 (en) 2005-08-10
JP2002503484A (ja) 2002-02-05
DE69936948T2 (de) 2008-05-15
KR100912362B1 (ko) 2009-08-19
KR101018992B1 (ko) 2011-03-07
AU757976B2 (en) 2003-03-13
ATE478945T1 (de) 2010-09-15
ES2272053T3 (es) 2007-04-16
HUP0100670A3 (en) 2003-10-28
ID28298A (id) 2001-05-10
AR020054A1 (es) 2002-04-10
EP1054955B1 (en) 2006-10-04
KR20090038927A (ko) 2009-04-21

Similar Documents

Publication Publication Date Title
HK1097413A1 (en) Compositions comprising viruses and methods for concentrating virus preparations
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
AU2064297A (en) Hepatitis c virus ribozymes
GB9811433D0 (en) Virus vaccine
HUP0103908A3 (en) Novel infulenza virus vaccine composition
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CZ20011341A3 (cs) Pomocné přípravky a vakciny
HK1023371A1 (en) Compositions and methods for treating viral infections
HUP0104548A3 (en) Hepatitis c inhibitor peptides, process for their preparation, pharmaceutical compositions conprising thereof and their use
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
EP1052988A4 (en) USEFUL METHODS AND COMPOSITIONS FOR INACTIVATING VIRUSES
AU7261898A (en) Methods for viral inactivation and compositions for use in same
EP1198468A4 (en) STABILIZED VIRAL ENVELOPE PROTEINS AND USES
AU4132096A (en) Compositions and methods for interfering with hepatitis b virus infection
AU8382198A (en) Methods for inactivating enveloped rna virus particles and compositions for use therewith
EP1068362A4 (en) HEPATITIS C VIRUS NS5B COMPOSITIONS AND METHOD FOR THEIR USE
GB9809666D0 (en) Modified viruses
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.
GB2351904B (en) Herbal composition and use of the composition for treating viral infection of the liver
GB9702990D0 (en) Virus vaccine
GB9707221D0 (en) Hepatitis B virus mutations
AU2002302069A1 (en) Virus preparations and methods
GB9908224D0 (en) Virus preparations and methods
AU5082698A (en) Heat inactivation of viruses in antibody preparations
AU2003204545A1 (en) Methods and compositions for inactivating viruses